A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians

Journal of the Canadian Urological Association

Volumn 4, Issue 4, 2010, Pages 269-275

  Morales, Alvaro ^a   Bella, Anthony J ^b   Chun, Samuel ^c   Lee, Jay ^d   Assimakopoulos, Peter ^e   Bebb, Richard ^f   Gottesman, Irv ^g   Alarie, Pierre ^h   Dugré, Hélène ⁱ   Elliott, Stacy ^j  

^a QUEEN S UNIVERSITY   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f ST PAUL S HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ UNIVERSITY OF MONTREAL   (Canada)

^j INTERNATIONAL COLLABORATION ON REPAIR DISCOVERIES   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957737638     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Bhasin S, Cunningham G, Hayes F, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-2559.
2. Dandona P, Dhindsa S, Chaudhuri A, et al. Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. Curr Mol Med 2008;8:816-828.
3. Liu PY, Beilin J, Meier C, et al. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J Clin Endocrinol Metab 2007;92:3599-3603.
4. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008;159:507-514.
5. United Nations DoEaS, Affairs Population D. World Population Prospects: The 2006 Revision, Highlights, Working Paper No. ESA/P/WP.202; 2007.
6. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239-1242.
7. Carruthers M. Time for international action on treating testosterone deficiency syndrome. Aging Male 2009;12:21-28.
8. Heufelder AE, Saad F, Bunck MC, et al. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726-733.
9. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004;90:871-876.
10. Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003;24:909-915.
11. Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006;27:57-64.
12. Gooren LJ, Behre HM, Saad F, et al. Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research. Aging Male 2007;10:173-181.
13. Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89:5462-5468.
14. Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006;295:1288-1299.
15. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl 1):S1-S201.
16. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335-4343.
17. Corona G, Jannini EA, Mannucci E, et al. Different testosterone levels are associated with ejaculatorydysfunction. J Sex Med 2008;5:1991-1998.
18. Tancredi A, Reginster JY, Schleich F, et al. Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol 2004;151:355-360.
19. Diver MJ, Imtiaz KE, Ahmad AM, et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003;58:710-717.
20. Rosner W, Auchus RJ, Azziz R, et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007;92:405-413.
21. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-3672.
22. Collier CP, Morales A, Clark A, et al The significance of biological variation in the diagnosis of testosterone deficiency, and considerations of the relevance of total, free and bioavailable testosterone determinations. J Urol 2010;183:2294-2299.
23. Spratt DI, O'Dea LS, Schoenfeld D, et al. Neuroendocrine-gonadal axis in men: frequent sampling of LH, FSH, and testosterone. Am J Physiol 1988;254:E658-E666.
24. Citron JT, Ettinger B, Rubinoff H, et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol 1996;155:529-533.
25. Bunch TJ, Abraham D, Wang S, et al. Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction. Aging Male 2002;5:38-46.
26. Rhoden EL, Estrada C, Levine L, et al. The value of pituitary magnetic resonance imaging in men with hypogonadism. J Urol 2003;170:795-798.
27. Prescribing Information: Depo-Testosterone (testosterone cypionate injection USP) 100 mg/mL Sterile solution. Kirkland, Quebec: Phizer Canada Inc.; 2007.
28. Prescribing Information: Delatestryl, testosterone enanthate, Solution for Injection, 200 mg/mL. Mississauga, Ontario: Theramed Corporation; 2007.
29. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004;89:503-510.
30. Product Monograph: Andriol (testosterone undecanoate capsules), 40 mg. Kirkland, Quebec: Schering-Plough Canada Inc.; 2008.
31. Product Monograph: pms-Testosterone (testosterone undecanoate) 40 mg Capsules. Montreal, Quebec: Pharmascience Inc; 2009.
32. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994;15:212-215.
33. Product Monograph: AndroGel, Testosterone gel, 1%. Markham, Ontario: Solvay Pharma Inc.; 2010.
34. Product Monograph: Testim 1% (testosterone gel). Malvern, Pennsylvania: Auxilium Pharmaceuticals Inc.; 2009.
35. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-2098.
36. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500-4510.
37. Dean JD, Carnegie C, Rodzvilla J, et al. Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Rev Urol 2005;7:87-94.
38. Product Monograph: Androderm Testosterone, Transdermal Delivery System, 12.2 mg and 24.3 mg. Montreal, Quebec: Paladin Labs Inc.; 2007.
39. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839-2853.
40. Jordan WP Jr, Atkinson LE, Lai C. Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin Ther 1998;20:80-87.
41. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75.
42. Ottenbacher KJ, Ottenbacher ME, Ottenbacher AJ, et al. Androgen treatment and muscle strength in elderly men: A meta-analysis. J Am Geriatr Soc 2006;54:1666-1673.
43. Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88:2673-2681.
44. Clopper RR, Voorhess ML, MacGillivray MH, et al. Psychosexual behavior in hypopituitary men: a controlled comparison of gonadotropin and testosterone replacement. Psychoneuroendocrinology 1993;18:149-161.
45. Rhoden EL, Morgentaler A. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice. J Sex Med 2010;7:277-283.
46. Zitzmann M. Testosterone and the brain. Aging Male 2006;9:195-199.
47. Pope HG Jr, Cohane GH, Kanayama G, et al. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 2003;160:105-111.
48. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-1972.
49. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab 2010;95:3-10.
50. Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl 2001;22:718-731.
51. Jockenhovel F, Minnemann T, Schubert M, et al. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. Eur J Endocrinol 2009;160:815-819.
52. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middleaged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451-1457.
53. Luboshitzky R, Aviv A, Hefetz A, et al. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J Clin Endocrinol Metab 2002;87:3394-3398.
54. Mohr BA, Bhasin S, Link CL, et al. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol 2006;155:443-452.
55. Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain 2009;25:170-175.